Isobacachalcone induces autophagy and improves the outcome of immunogenic chemotherapy

Qi Wu1,2,3,4, Ai-Ling Tian2,3,4, Sylvère Durand2,3, Fanny Aprahamian2,3, Nitharshshini Nimalathasan2,3, Wei Xie2,3,4, Peng Liu2,3,4, Liwei Zhao2,3,4, Shuai Zhang2,3,4, Hui Pan2,3,4, Didac Carmona-Gutierrez5,6,7, Frank Madeo5,6,7, Yi Tu1, Oliver Kepp2,3 and Guido Kroemer2,3,8,9,10

Abstract
A number of natural plant products have a long-standing history in both traditional and modern medical applications. Some secondary metabolites induce autophagy and mediate autophagy-dependent healthspan- and lifespan-extending effects in suitable mouse models. Here, we identified isobacachalcone (ISO) as a non-toxic inducer of autophagic flux that acts on human and mouse cells in vitro, as well as mouse organs in vivo. Mechanistically, ISO inhibits AKT as well as, downstream of AKT, the mechanistic target of rapamycin complex 1 (mTORC1), coupled to the activation of the pro-autophagic transcription factors EB (TFEB) and E3 (TFE3). Cells equipped with a constitutively active AKT mutant failed to activate autophagy. ISO also stimulated the AKT-repressible activation of all three arms of the unfolded stress response (UPR), including the PERK-dependent phosphorylation of eukaryotic initiation factor 2α (eIF2α). Knockout of TFEB and/or TFE3 blunted the UPR, while knockout of PERK or replacement of eIF2α by a non-phosphorylable mutant reduced TFEB/TFE3 activation and autophagy induced by ISO. This points to crosstalk between the UPR and autophagy. Of note, the administration of ISO to mice improved the efficacy of immunogenic anticancer chemotherapy. This effect relied on an improved T lymphocyte-dependent anticancer immune response and was lost upon constitutive AKT activation in, or deletion of the essential autophagy gene Atg5 from, the malignant cells. In conclusion, ISO is a bioavailable autophagy inducer that warrants further preclinical characterization.

Introduction
Macroautophagy (to which we herein refer as “autophagy”) is a unique cell biology phenomenon that leads to cytoplasmic vacuolization in response to nutrient deprivation as well as to a myriad of other cell stress-inducing conditions1. Portions of the cytoplasm are enveloped in two-membraned vesicles, the autophagosomes, which then fuse with lysosomes for the digestion of the autophagic cargo by hydrolases that operate at acidic pH2,3. Autophagy allows to mobilize the cell’s energy reserves by digestion of cytoplasmic macromolecules and even entire organelles to recover their building blocks, including amino acids, simple sugars, and free fatty acids4. In addition, autophagy allows for the selective degradation of superficial, damaged, or aged cellular components, including dysfunctional organelles and potentially pathogenic protein aggregates. Genetic stimulation of autophagy has potent antiaging properties, reducing the manifestation of age-associated diseases, including arteriosclerosis, cancer, and neurodegeneration5–7. Pharmacological induction of autophagy has similar broad healthspan and lifespan-extending effects, as shown in model organisms including yeast, nematodes, flies, and mice8–11. Obviously, there is much interest in identifying novel autophagy inducers that operate at low levels of toxicity...
and mediate broad antiaging and pro-health effects. Chalcones belong to the chemical class of flavonoids and are contained in multiple plants that are reputed for their dietary virtues. Based on these considerations, we have set out in the past to identify autophagy-inducing chalcones. Among a homemade library of chalcones, we identified two different agents, namely, 4,4′-dimethoxychalcone (4,4′-DMC) and its isomer 3,4-dimethoxychalcone (3,4-DMC) as potent autophagy inducers. Of note, both chalcones differ in their mode of action. While 4,4′-DMC inhibits autophagy-suppressive GATA transcription factors, 3,4-DMC acts through the activation of the two related pro-autophagic transcription factors EB (TFEB) and E3 (TFE3). Irrespective of this difference, both 4,4′-DMC and 3,4-DMC reduce myocardial infarction in mice. Moreover, 4,4′-DMC extended the lifespan of yeast, nematodes, and flies, while 3,4-DMC enhanced anti-ancer immune responses in mice. These preclinical data plead in favor of a potential medial utility for chalcones.

Driven by these considerations, we decided to identify additional pro-autophagic chalcones by screening another collection of agents. Here, we demonstrate that isobacachalcone (ISO) stimulates autophagic flux, delineate the molecular pathways involved in this effect, and suggest clinical utility for this chalcone as a stimulator of anticancer immunity in the context of immunogenic cell death (ICD)-inducing chemotherapy.

Results
Identification of ISO as an inducer of autophagic puncta

Human neuroglioma H4 cells stably transduced with a fusion protein containing green fluorescent protein (GFP) in the N- and microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B, best known as LC3) in the C-terminus (GFP-LC3) were cultured in the presence of each of the chalcones contained in the Polyphenolic Natural Compound Library from TargetMol, each used at three different concentrations (10, 25, and 50 μM). We found that ISO, (E)-1-[2,4-dihydroxy-3-(3-methyl-2-butenyl)-phenyl]-3-(4-hydroxyphenyl)-2-propen-1-one or (E)-4,2′,4′-trihydroxy-3′-propenylchalcone; 2′,4′,4′-trihydroxy-3′-prenyl-transchalcone) consistently induced GFP-LC3 puncta at doses of 25 and 50 μM (Fig. 1A–C). This effect was coupled to a reduction in cytoplasmic protein acetylation that could be measured by immunofluorescence assays using antibodies that recognize acetylated lysine residues (Fig. 1D, E). ISO also induced the lipidation of LC3, measurable by immunoblot analyses (in which LC3 lipidation yields a band with higher electrophoretic mobility, i.e., LC3B or LC3-II) that was even observed in the presence of bafilomycin A1, an inhibitor of autophagosome-lysosome fusion, suggesting that ISO induces autophagic flux (Fig. 1F, G). Simultaneously, ISO reduced the abundance of hemagglutinin (HA)-tagged sequestosome 1 (SQSTM1, best known as p62) fusion protein transfected into the cells, again supporting the idea that ISO stimulates autophagic flux (Fig. 1F, H). In human osteosarcoma U2OS cells, ISO also induced GFP-LC3 puncta but failed to do so upon knockout of the essential autophagy gene ATG5 (Fig. 1I–K), indicating that the formation of GFP-LC3 puncta is indeed coupled to autophagy. In sum, it appears that ISO is a chalcone endowed with autophagy-stimulatory properties.

ISO induces autophagic puncta through the inhibition of AKT

ISO is known to inhibit protein kinase B (PKB, best known as AKT). Indeed, U2OS cells stably expressing a GFP-AKT fusion protein responded to stimulation with recombinant insulin growth factor-1 (rIGF1) by a partial translocation of the fluorescent signal to the plasma membrane, reflecting AKT activation. This effect was not detectable for a loss-of-function mutation of AKT consisting of an arginine-to-cysteine mutation in the pleckstrin homology domain of AKT (R25C) (Fig. 2A, B). In addition, ISO inhibited the activating phosphorylation of AKT (Ser473) as well as, downstream of AKT, the phosphorylation of mechanistic target of rapamycin (mTOR) (Ser448), and the mTOR complex 1 (mTORC1)-dependent phosphorylation of S6K (Thr389) (Fig. 2C). Stable transfection of U2OS cells with a constitutively active AKT mutant (T308D/S473D) inhibited the formation of ISO-induced GFP-LC3 puncta (Fig. 2D, E) as well as the lipidation of LC3 (Fig. 2F, G). In conclusion, it appears that ISO stimulates autophagy through the inhibition of AKT.

ISO induces autophagic flux in vitro and in vivo

Next, we determined whether ISO induces actual autophagic flux by means of several fluorescent reporter-based assays. First, we took advantage of a cell line stably expressing an RFP-ATG4-GFP-LC3ΔG. When expressed in cells, the probe is cleaved into a stable/cytosolic part, RFP-LC3ΔG (that serves as an internal control) and a degradable/quenchable part, GFP-LC3 (which is destroyed by autophagy). Hence, a diminution of the GFP-to-RFP ratio indicates the occurrence of autophagy. ISO consistently induced a decrease in the GFP-to-RFP ratio of cells expressing RFP-ATG4-GFP-LC3ΔG (Fig. 3A, C). We also used cells stably expressing a mCherry-GFP-p62 tandem fusion protein, in which the low pH-sensitive GFP-dependent fluorescence (but less so the pH-resistant mCherry fluorescence) was reduced upon the culture of the cells with ISO (Fig. 1B, D). Similarly, we used a rat adrenal gland (pheochromocytoma) PC12 cell line expressing a tetracycline-inducible variant of Q74-GFP, meaning that the GFP via a polyglutamine tail forms aggregates in the cytoplasm that can be degraded by macroautophagy.
Fig. 1 (See legend on next page.)
Again, we found that ISO reduced the number of Q74-GFP dots in this experimental system, supporting the idea that it indeed stimulates autophagic flux.

Encouraged by these findings, we determined whether ISO might inhibit the Akt pathway and induce autophagy in vivo. Multiple immunoblot experiments indicated that ISO reduces Akt, mTOR, and S6K phosphorylation while it enhances the abundance of LC3-II in the heart or liver of mice receiving intraperitoneal (i.p.) ISO injections. Thus, ISO can stimulate autophagy in vivo. Notably, the in vivo effects of ISO were not accompanied by measurable weight loss, suggesting that ISO is not toxic.

ISO induces TFEB/TFE3 activation and ER stress

U2OS cells exposed to ISO showed the translocation of a TFEB-GFP fusion protein from the cytoplasm to the nucleus (Fig. 4A, B). Similarly, TFE3 detectable by immunofluorescence translocated to the nucleus upon culture with ISO (Fig. 4C, D). The nuclear translocation of TFEB and TFE3 could be confirmed by cellular fractionation and immunoblot detection of the two transcription factors in the cytoplasm and nuclei (Fig. 4E–G). Accordingly, knockout of TFEB alone (Fig. 4H–K), TFE3 alone (Fig. 4L–O), or their double knockout (genotype: TFEB<sup>−/−</sup> TFE3<sup>−/−</sup>) blunted the induction of autophagic GFP-LC3 puncta and the lipodization of LC3.

In U2OS cells equipped with biosensors of endoplasmic reticulum (ER) stress, we found that ISO induced the upregulation of CHOP (measured by using a GFP gene inserted into the genome under the control of the CHOP promoter, Fig. 5A, B) and activated the IRE1/XBP1 axis (measured by means of an XBP1ΔDBD-venus fusion protein<sup>19</sup> that is only in-frame for venus, a variant of GFP, when XBP1 has been spliced by IRE1, Fig. 5C, D). Similar results were obtained when signs of ER stress were measured by immunofluorescence to detect the nuclear presence of CHOP (Fig. 5E, F) and ATF6 (Fig. 5G, H), the phosphorylation of eukaryotic initiation factor 2α (eIF2α) on serine 51 (Fig. 5I, J) and the expression of the spliced isoform of XBP1 (XBP1s) (Fig. 5K, L). In most of the cases, the ISO-induced signs of ER stress were comparable in magnitude to those induced by the positive controls thapsigargin (TG) and tunicamycin (TM) (Fig. 5A–L). Moreover, the expression of constitutively active Akt mutant blunted the signs of ER stress induced by ISO (Fig. 5E–L).

Interestingly, a crosstalk between the pro-autophagic and the ER stress-inducing activities of ISO was observed. Thus, <sup>−/−</sup> <sup>−/−</sup> cells exhibited a reduced activation of CHOP (Supplementary Fig. S1A, B) and ATF4 (Supplementary Fig. S1C, D). Such a reduced CHOP and ATF4 activation was also found for the single-gene knockout of TFEB or TFE3 (Supplementary Fig. S2). Cells lacking the elf2α kinase 3 (EIF2AK3, best known as PERK) exhibited reduced phosphorylation of elf2α in response to ISO (Supplementary Fig. S1E, F), coupled to reduced formation of autophagic RFP-LC3 puncta (Supplementary Fig. S1G, H). Both the knockout of PERK and a knock-in mutation of elf2α rendering it non-phosphorylatable (due to the substitution of serine 51 by an alanine residue: S51A) significantly reduced the activation of TFE3 by ISO (Supplementary Fig. S1I–L). These findings suggest molecular crosstalk between the TFEB/TFE3 and the PERK/elf2α pathways triggered by ISO.

ISO improves the outcome of immunogenic chemotherapy

Although ISO alone had rather scarce cytotoxic activities, it was able to amplify the ATP release induced by treatment of U2OS cells with low doses of an ICD inducer (mitoxantrone, MTX), as determined by staining of cells with the ATP biosensor quinacrine (Fig. 6A, B) or by

(see figure on previous page)

**Fig. 1** Isobacachalcone (ISO) is a candidate caloric restriction mimetic (CRM). A Human neuroglioma H4 cells stably expressing GFP-LC3 were treated with a selection of chalcones from the TargetMol library of flavonoids at the indicated concentrations. We compared the selected agents at different concentrations with the standard autophagy inducer torin 1 (300 nM), and identified conditions with significantly increased GFP-LC3 puncta formation (1.25 times of the vehicle control (DMSO)) and viability of at least 80% with respect to DMSO, as potent autophagy activation. B, C H4 cells stably expressing GFP-LC3 were treated with isobacachalcone (ISO) (10, 25, and 50 μM) for 6 h. Then the cells were fixed and imaged to assess the formation of GFP-LC3 puncta. Torin 1 (300 nM) was used as a prototypical autophagy inducer. Representative images are shown in (B). Scale bar equals 10 μm. Data are means ± SD of quadruplicates ("P < 0.01 vs. DMSO/Ctr, Student’s t test). D, E U2OS cells were treated as described above, followed by the incubation with specific antibodies to block acetylated tubulin. Thereafter, immunofluorescence was conducted with antibodies against acetylated lysine residues and appropriate AlexaFluor-conjugated secondary antibodies. Representative images of lysine acetylation are shown in (D), and the decrease of acetylation in the cytoplasm was measured in (E). Scale bar equals 10 μm. Data are means ± SD of quadruplicates ("P < 0.01 vs. DMSO/Ctr, Student’s t test).
measuring ATP in the supernatant of the cells using a biochemical assay (Fig. 6C–F). ATP is released from stressed cancer cells in an autophagy-dependent fashion\(^{20,21}\) and acts in the extracellular space as an important chemotactic factor that attracts myeloid immune effectors into the tumor bed, thereby setting off the molecular cascade that permits anticancer immune responses in the context of ICD\(^{22,23}\). In contrast, ISO did not affect other autophagy-independent hallmarks of ICD\(^{24}\), including surface exposure of calreticulin or the release of high mobility group protein B1 from low-dose MTX-treated cells (Supplementary Fig. S3). Of note, the knockouts of ATG5 (Fig. 6C) or PERK (Fig. 6D), the S51A mutation of eIF2\(\alpha\) (Fig. 6E) or the expression of a constitutively active AKT mutant (Fig. 6F) reduced the ATP release induced by the combination of low-dose MTX and ISO, supporting the idea that the aforementioned pathways are important for this phenomenon.

Next, we determined the capacity of ISO to enhance the efficacy of ICD-inducing chemotherapy in vivo, using immunocompetent mice-bearing syngeneic cutaneous MCA205 fibrosarcomas. We chose this type of methylcholanthrene-induced tumor because it is well characterized in immunosurveillance models\(^{25,26}\), and because its growth under the skin can be considered as orthotopic. Once MCA205 tumors had been established, the mice received the ICD inducer oxaliplatin (OXA), ISO or the combination (OXA + ISO) while negative controls received vehicle alone (Fig. 6G). Of note, the combination
(OXA + ISO) allowed for tumor growth control in conditions in which ISO and OXA alone had no or little effect, respectively (Fig. 6H). The anticancer activity depended on the immune system since it was lost in mice lacking mature T cells due to the nu/nu mutation that causes athymia (Fig. 6I). Moreover, tumor cells engineered to lack
Atg5 or to express constitutively active Akt failed to respond to the ISO/OXA combination treatment in the immunocompetent setting (Fig. 6j, k). Analysis of the immune infiltrates of the tumors treated with ISO, OXA, or ISO + OXA (Fig. 6l) revealed that the combination treatment was particularly efficient in reducing regulatory T cells (Tregs, defined as CD3εCD4εFoxP3ε cells), in improving the ratio of CD8ε cytotoxic T lymphocytes (CTLs) over Tregs and in reducing the expression of the exhaustion marker PD-1 on CTLs (Fig. 6m–p). In conclusion, ISO stimulates anticancer immunity in the context of ICD-inducing chemotherapy.

Discussion

Here, we identified ISO as an autophagy inducer that inhibits Akt and mTORC1 activity and activates the pro-autophagic transcription factors TFEB and TFE3, which both are known to be activated by mTORC1 inhibition27,28. We also found that ISO activates a broad ER stress response including the PERK-dependent phosphorylation of eIF2α, as a sign of the integrated stress response, which is known to be required for autophagy induction29–31 as well as for the induction of ICD32–37. The two pathways, autophagy and ER stress induced by ISO exhibited crosstalk in thus far that (i) they both are inhibited by constitutively active Akt, (ii) TFEB/TFE3 knockout does not only reduce autophagy but also signs of ER stress, and (iii) PERK knockout or substitution of eIF2α by a non-phosphorylatable mutant reduces TFEB/TFE3 activation and autophagy. Beyond these in vitro phenomena, ISO induced autophagy in vivo, in mouse tissues, and enhanced the immune response induced by immunogenic chemotherapy against established tumors, thus improving tumor growth control through mechanisms that rely on T cells as well as Akt inhibition and autophagy induction in the cancer cells.

ISO is a chalcone that was first isolated from the multipurpose medical plant Psoralea corylifolia. Reportedly, ISO possesses a wide spectrum of antibacterial38,39, antifungal40, antiparasitic41, antiviral42,43, antitubercular44, antithrombotic45,46, antiinflammatory47,48, antioxidant49, antiobesity50, and phytoestrogen51 activities. Hence, ISO has a very broad range of biological activities. In cell-free enzymatic assays, ISO inhibits beta-secretase52, acyl-coenzyme A: cholesterol acyltransferase53, severe acute respiratory syndrome coronavirus (SARS-CoV) papain-like protease54, protein tyrosine phosphatase 1B (PTP1B)55, carboxylesterase 256, and pancreatic lipase57, suggesting that ISO can act on multiple pharmacological targets, shedding doubts on its specificity. Based on its broad effects, it might be suspected that ISO has direct immunostimulatory effects that help to improve immunosurveillance in the context of ICD-inducing chemotherapies. Indeed, autophagy induction may stimulate dendritic and T-cell functions23,58,59.

In vitro, ISO reduces Aβ42 aggregation in SH-SYSY cells60, and the tumor necrosis factor-α (TNFα)–induced atrophy of C2C12 myotubes61. In rodents, ISO attenuates Parkinson’s disease induced by the toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)62, sephadex-induced lung injury63, as well as streptozotocin-induced diabetic nephropathy64. This suggests that ISO has a wide range of cytoprotective effects that might be explained by its autophagy-inducing activity.

With respect to its anticancer effects, ISO reportedly suppresses skin tumor promotion in an in vivo two-stage mouse skin carcinogenesis test using 7,12-dimethylbenz[a]anthracene (DMBA) as an initiator and 12-O-Tetradecanoylphorol-13-acetate (TPA) as a promoter65. ISO has cytotoxic effects on neuroblastoma66, multiple myeloma cells67,68, leukemia69, as well as on chemoresistant carcinoma and glioblastoma cell lines70, enhances TRAIL-induced apoptosis in prostate cancer and cervical carcinoma cells71, and reduces melanin production by B16 melanoma cells72. Here, we found that ISO failed to inhibit the growth of fibrosarcomas in mice when used as a standalone treatment, yet ameliorated the efficacy of ICD-inducing chemotherapy through an improved anticancer immune response. The absence of antitumor efficacy of ISO, when used as a standalone treatment, may
be linked to suboptimal dosing as well as to its pharmacokinetics, knowing that ISO has a half-life of ~6 h in rats. However, we have observed as a general pattern that autophagy induction with non-toxic agents is not sufficient to inhibit tumor growth of established tumors in mice. Thus, the biological activity of ISO is reminiscent of other autophagy inducers including 3,4-DMC, hydroxycitrate, resveratrol, spermidine, and thiostrepton, all of which can ameliorate the therapeutic activity of ICD inducers in suitable mouse models but lack intrinsic anticancer properties.

Although ISO has multiple pharmacological effects and targets, several of the in vitro effects of ISO correlated with the inhibition of the AKT/mTORC1 pathway, and expression of a constitutively active AKT mutant largely reversed the ISO-induced signs of cellular stress including autophagy (with its upstream events, mTORC1 inhibition and TFE3 activation) and ER stress (at all levels of the unfolded stress response, including its PERK/eIF2α/ATG4/CHOP, ATG6, and IRE1α/XBP1 arms), as shown in human U2OS cells. Moreover, mouse cancer cells stably expressing a constitutively active AKT enzyme...
(or lacking the essential autophagy gene Atg5) became resistant against the anticancer activity of ISO combined with ICD induction, suggesting some sort of ‘specificity’ for the ISO effect. However, at this point, it is not clear whether ISO may directly inhibit AKT or an enzyme upstream of AKT (such as phosphatidylinositol 3-kinases). Reportedly, ISO inhibits PTP1B, which would result in the activation, not the inhibition of the AKT pathway. Hence, the precise molecular target of ISO remains elusive.

ISO was initially isolated from Psoralea corylifolia, but it has also been identified in other plants, including Angelica keiskei, Arctocarpus species, Cullen corylifolium, Dorstenia barteri, Erythrea fusca, Fatoua pilosa, Morus alba, and Piper longum. This suggests that ISO is rather prevalent in plants, perhaps contributing to the broad pro-health effects of plant-enriched diets. However, additional studies are required to confirm this conjecture.

In summary, here we identified a particular chalcone, ISO, as a potent autophagy inducer that acts in vitro and in vivo, on human cell lines and mouse organs, respectively. Through the induction of autophagy, ISO is able to stimulate anticancer immune responses in the context of immunogenic chemotherapy.

Materials and methods

Cell culture and chemicals

Culture media and supplements for cell culture were obtained from Life Technologies (Carlsbad, California, USA) and plastic materials came from Greiner Bio-One (Kremsmünster, Austria) and Corning (Corning, NY, USA). Rat adrenal gland PC12 cells stably expressing doxycycline-inducible Q74-GFP were cultured in Roswell Park Memorial Institute (RPMI)-1640 containing 5% fetal bovine serum and 10% horse serum. Human neuroglioma H4 cells, human osteosarcoma U2OS cells, MCA205 murine fibrosarcoma, and all the other cells were maintained in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% (v/v) fetal bovine serum (FBS), 10 U mL⁻¹ penicillin sodium and 10 μg mL⁻¹ streptomycin sulfate at 37 °C in a humidified atmosphere with 5% CO₂.

Results

Cell culture and chemicals

Human osteosarcoma U2OS cells stably expressing GFP-TFEB fusion protein were treated with torin 1 (300 nM) and isoibuzacalcone (ISO, 25 μM) for 6 h. Representative images are shown in (A) and TFEB translocation was assessed by measuring GFP intensities in the nuclei (B). Scale bar equals 10 μm. Data are means ± SD of quadruplicates (P<0.001 vs. DMSO/Ctr, Student's t-test). C D U2OS cells were treated with torin 1 (300 nM) and ISO (25 μM) for 6 h, and then, endogenous TFEB translocation was assessed by immunostaining (C). Nuclear TFEB intensities are depicted in (D). Scale bar equals 10 μm. Data are means ± SD of quadruplicates (P<0.001 vs. DMSO/Ctr, Student's t-test). E-G U2OS cells were treated with ISO (25 μM) for 6 h or were left untreated. Cytoplasmic and nuclear fractions were assessed for nuclear translocation of the transcription factors TFEB and TF3 in parallel samples by SDS–PAGE. GAPDH and H3 were used to ensure equal loading in the cytoplasmic and nuclear fractions, respectively. Band intensities of TFEB, TF3, GAPDH, and H3 were assessed and their ratios (TFEB or TF3/GAPDH, and TFEB or TF3/H3) were calculated in (F, G). (P<0.05, **P<0.01, ***P<0.001 vs. cytoplasmic DMSO; **P<0.05, ***P<0.01, ****P<0.001 vs. nuclear DMSO; Tukey’s multiple comparisons test). H-K U2OS cells stably expressing GFP-LC3 either wild-type (WT) or knockout for TFEB were treated with torin 1 (300 nM) or ISO (25 μM) for 16 h. LC3-II expression and TFEB deficiency were visualized by SDS–PAGE and immunoblot (J). Band intensities of LC3-II and β-actin (ACTB) were assessed, and their ratio (LC3-II/ACTB) was calculated in (K). Representative images are shown in (H), and GFP-LC3 dots were quantified as indicators of autophagy (I). Scale bar equals 10 μm. Data are means ± SD of quadruplicates (P<0.001 vs. untreated control; P<0.05 vs. WT, Tukey’s multiple comparisons test). L-O U2OS cells stably expressing GFP-LC3 either WT or knockout for TFEB were treated with torin 1 (300 nM) and ISO (25 μM) for 16 h. LC3-II expression and TFEB deficiency were monitored by SDS–PAGE and immunoblot (N). Band intensities of LC3-II and ACTB were assessed, and their ratio (LC3-II/ACTB) was calculated in (O). Representative images are shown in (L), and GFP-LC3 dots were quantified (M). Scale bar equals 10 μm. Data are means ± SD of quadruplicates (P<0.05, **P<0.001 vs. untreated control; *P<0.05 vs. WT; Tukey’s multiple comparisons test). P-S U2OS cells stably expressing GFP-LC3 either wild-type or double knockout for TFEB and TF3 cells were treated with torin 1 (300 nM) and ISO (25 μM) for 16 h. LC3-II expression and TFEB/TF3 deficiency were checked in parallel samples by SDS–PAGE and immunoblot (R). Band intensities of LC3-II and ACTB were assessed, and the ratio (LC3-II/ACTB) was calculated (S). Representative images are shown in (P), and GFP-LC3 dots were quantified as indicators of autophagy (Q). Scale bar equals 10 μm. Data are means ± SD of quadruplicates (P<0.05, ***P<0.001 vs. untreated control; *P<0.05, **P<0.01 vs. WT, Tukey’s multiple comparisons test).
Fig. 5 (See legend on next page.)
High-content microscopy

Human osteosarcoma U2OS and neuroglioma H4 cells stably expressing GFP-LC3 or RFP-LC3 and rat adrenal gland PC12 cells stably expressing doxycycline-inducible Q74-GFP were seeded in 384-well black imaging plates at a density of 2000 cells per well and allowed to adapt for overnight. Cells were treated with the indicated agents for 6 h, subsequently, cells were fixed with 3.7% paraformaldehyde (PFA, w/v in PBS) (F8775, Sigma-Aldrich) at 4 °C overnight and stained with 1 µg/ml Hoechst 33342 (H3570, Thermo Fisher Scientific) against the primary antibody (Greiner Bio-One) and let adhere overnight. Cells were then treated for 6 h to detect TFE3 promoter activity. For CALR redistribution and HMGB1 release, cells were incubated for 8 h or 24 h respectively. Next, cells were fixed with 3.7% formaldehyde supplemented with 1 µg/ml Hoechst 33342 (H3570, Thermo Fisher Scientific) at 4 °C overnight. The tissues (~30 mg) were dissociated in Precellys lysing tubes (#89901, Invitrogen, Carlsbad, CA, USA) by using the Precellys 24 homogenizer (Bertin Technologies SAS) at 6500 rpm for 5 min, followed by spinning at 14,000×g for 15 min to collect the supernatant that contains soluble proteins. For cells, the protein extracts were dissolved in protein extract buffer (4× loading buffer (# NP0008, Invitrogen), and denatured at 100 °C for 15 min before subjected to western blotting. The total protein (~30 µg) were resolved on

Immunofluorescence

Human osteosarcoma U2OS cells were treated for 6 h to detect eIF2α phosphorylation (PeIF2α) and TFE3, 16 h to assess ATF6 and spliced XBP1 (XBP1s) levels, or 24 h to measure CHOP expression. Then cells were fixed by 3.7% PFA at 4 °C overnight. For staining, fixed cells were permeabilized with 0.1% Triton X100 on ice, and blocked with 5% bovine serum albumin (BSA, w/v in PBS) for 1 h. Next, cells were incubated with antibodies specific to TFE3 (#ab93808, 1:400, Abcam), phospho-eIF2α alpha (Ser51) (#ab32157, 1:1000, Abcam), ATF6 (#ab37149, 1:200, Abcam), XBP1 (#ab37152, 1:250, Abcam) or CHOP (#2895, 1:500, Cell Signaling Technology) at 4 °C overnight. After washed by PBS twice, AlexaFluor conjugates (Thermo Fisher Scientific) against the primary antibody were applied for 2 h at RT. Finally, cells were washed and imaged by automated fluorescence microscopy as described above. The nuclear intensity of TFE3, ATF6, XBP1s or CHOP and cytoplasmic intensity of phospho-eIF2α (Ser51) were measured and normalized on Ctrl.
Fig. 6 ISO mediates improvement of anticancer chemotherapy. A, B Human osteosarcoma U2OS cells were treated with isobacachalcone (ISO, 25 μM) in the presence of low doses of the immunogenic cell death (ICD) inducer mitoxantrone (MTX, 1 μM) for 6 h. High-dose MTX (5 μM) was used as a positive control. The ATP-sensitive agent quinacrine was used to monitor intracellular ATP content. Representative images are shown in (A), and the abundance of quinacrine was quantified in (B). Scale bar equals 10 μm. Data are means ± SD of quadruplicates (*P < 0.05, **P < 0.01 vs. untreated control Tukey’s multiple comparisons test).

C-F Human neuroglioma H4 cell stably expressing GFP-LC3 either wild-type (WT) or ATG5 knockout, human osteosarcoma U2OS wild-type, PERK knockout or eIF2α S51A knock-in cells, murine fibrosarcoma MCA205 WT or AKT T308D/S473D knock-in cells were treated with ISO (25 μM) alone or in combination with low doses of MTX (1 μM) for 6 h, as described above. High-dose MTX (5 μM) was used as a positive control. Extracellular ATP levels were measured by luciferase conversion (**P < 0.01, ***P < 0.001 vs. untreated control; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. WT; Tukey’s multiple comparisons test).

G, L Schematic overview of the in vivo treatment of murine fibrosarcoma MCA205-bearing mice with oxaliplatin (OXA) and ISO, alone or in combination. H-K Growth kinetic of murine fibrosarcoma MCA205 cells WT (H), Atg5KD (J), or AKT T308D/S473D knock-in (K) growing in immunocompetent C57BL/6 mice, treated as indicated in (G). Athymic mice (nu/nu) mice (I) were inoculated subcutaneously with murine fibrosarcoma MCA205 cells. When tumors became palpable, mice received a systemic intraperitoneal injection of ISO alone or together with OXA. n ≥ 6 mice per group. Results (means ± SD tumor growth curves) are plotted (*P < 0.05 or ns, not statistically significant vs. OXA).

M–P Murine fibrosarcoma MCA205 cells were evolving in immunocompetent C57BL/6 mice, treated as indicated in (L). Cytofluorometric characterization of tumor-infiltrating lymphocytes, in particular CD4+FOXP3+CD25+ regulatory T cells (Treg) (M), CD3+CD8+ cytotoxic T lymphocytes (N), CD8+PD1+ T lymphocytes (O), and the ratio of CD3+CD8+ T cells over Treg (P) are depicted. Data are means ± SD (n ≥ 5) (P < 0.05 or ns, not statistically significant vs. OXA; Student’s t test).
Nuclear extraction experiment

U2OS-GFP-LC3 cells were collected and processed with the Nuclear Extraction Kit (#ab113474, Abcam) following the manufacturer's methods. The GAPDH antibody (#2118, 1:1000, Cell Signaling Technology) was used as the cytoplasmic control, and H3 (#9715, 1:1000, Cell Signaling Technology) was selected as the nuclear control.

Detection of protein deacetylation

U2OS cells stably expressing GFP-LC3 (~2000 cells/well) were seeded in 384-well microplates overnight. After experimental treatments, cells were fixed with 3.7% PFA containing 10 μg/ml Hoechst 33342 overnight at 4°C. Thereafter, cells were incubated with an antibody specific for acetyl-alpha-tubulin (#5335, 1:500, Cell Signaling Technology) in 5% BSA (w/v in PBS) for 1 h to block non-specific binding sites and acetylated tubulins, followed by overnight incubation at 4°C with an antibody specific to acetylated lysine residues (#623402, 1:400, BioLegend, San Diego, California, USA). After washing three times with PBS, cells were incubated in AlexaFluor-568-conjugated secondary antibodies (Life Technologies) for 2 h at room temperature. Fluorescent images were acquired and analyzed as described before.

ATP release assays

Intracellular ATP levels were detected by quinacrine stain assay (Calbiochem) kits, subsequently, the images of quinacrine were obtained by high-content microscopy and the cytoplasmic intensity of quinacrine was quantitated described above. Extracellular ATP levels were measured by the ENLITEN ATP Assay System Bioluminescence Detection Kit (Promega, Madison, Michigan, USA; #FF2000) following the manufacturer's methods. Luminescence was detected by means of a Paradigm I3 multimode plate reader (Molecular Devices).

Animal experimentation

The animal experiments were approved by the Gustave Roussy ethical committee with project number 24771–2020032413235413, and all procedures were performed under the governmental and institutional guidelines and regulations. All mice were maintained in a temperature-controlled and pathogen-free environment with 12-h light/dark cycles, with food and water ad libitum. Animal experiments were conducted in compliance with the EU Directive 63/2010 and protocols 2019_030_20590 and were approved by the Ethical Committee of the Gustave Roussy Campus Cancer (CEEA IRCIV/IGR no. 26, registered at the French Ministry of Research).

For tumor growth experiments, 7-week-old female wild-type C57BL/6 mice or athymic female nude mice (nu/nu) were obtained from Envigo, France (Envigo, Huntingdon, UK). MCA205 wild-type (WT), or continuous activation of AKT T308D/S473D cells (4 × 105), MCA205 cells carrying an ATG5 knockdown (WT, 6 × 105) were subcutaneously injected into C57BL/6 hosts. When tumors became palpable, mice were treated with 20 mg/kg ISO dissolved in corn oil (Sigma-Aldrich) or an equivalent volume of vehicle alone or in combination with 10 mg/kg oxaliplatin (OXA, Sigma-Aldrich) by intraperitoneal injection. On the following days, mice well-being and tumor growth were monitored and documented. Animals were sacrificed when tumor size reached the ethical endpoint or signs of obvious discomfort were observed following the EU Directive 63/2010 and our Ethical Committee advice.

Ex vivo phenotyping of the tumor immune infiltrate

Tumors were harvested, weighed, and transferred on ice into gentleMACS C tubes (Miltenyi Biotec, Bergisch Gladbach, Germany) containing 1 mL of RPMI medium.
Tumors were dissociated first mechanically with scissors, then enzymatically using Miltenyi Biotec mouse tumor dissociation kit (Miltenyi Biotec) and a GentleMACS Octo Dissociator according to the manufacturer’s instructions. The dissociated bulk tumor cell suspension was resuspended in RPMI-1640, sequentially passed through 70-μm MACS Smart-Strainer (Miltenyi Biotec), and washed twice with PBS. Finally, bulk tumor cells were homogenized in PBS at a concentration corresponding to 250 mg of the initial tumor weight per milliliter. Prior to staining of samples (~50 mg) were incubated with LIVE/DEAD® Fixable Yellow Dead Cell dye (Thermo Fisher Scientific) to discriminate viable cells from damaged cells. Fc receptors were blocked with anti-mouse CD16/CD32 (clone 2.4G2, Mouse BD Fc Block, BD Pharmingen) before staining with fluorescent-labeled antibodies targeting T-cell surface markers. Surface staining of murine immune cell populations infiltrating the tumor was performed with the following fluorochrome-conjugated antibodies: anti-CD45-AF700, anti-CD3-BV421, anti-CD8-PE, anti-CD4-PerCp.Cy5.5, anti-CD25-PE/Cy7, and anti-PD-1-APC/Cy7 (BioLegend). Then, cells were fixed and permeabilized in eBioscience Foxp3/Transcription Factor Staining Buffer (Thermo Fisher Scientific) and stained for intracellular Foxp3. Finally, stained samples were run through a BD LSR II flow cytometer. Data were acquired using BD FACSDiva software (BD Biosciences) and analyzed using FlowJo software (TreeStar). Absolute counts of leukocytes and tumor cells were normalized considering the following parameters: the weight of the harvested tumor and total volume of the dissociated tumor cell suspension (cell concentration typically set to 250 mg/mL in PBS), the proportion of the whole-cell suspension, and proportion of the cell suspension used for cytometry.

Statistical analysis

Unless otherwise mentioned, data are reported as means ± SD of triplicate determinations, and experiments were repeated at least three times yielding similar results. Statistical significance was assessed by Student’s t test. TumGrowth and GraphPad were used to analyze in vivo data arising from murine models. TumGrowth is available at Github/Kroemerlab. P values of 0.05 or less were considered to denote significance (‘P < 0.05; ‘‘P < 0.01; ‘‘‘P < 0.001; ns, not significant).
of immunogenic cell stress.

Wu et al.

Page 15 of 16

Official journal of the Cell Death Differentiation Association
64. Dong, W. H., Chu, Q. Q., Liu, S. Q., Deng, D. T. & Xu, Q. Isobavachalcone ameliorates diabetic nephropathy in rats by inhibiting the NF-kappaB pathway. J. Food Biochem. e13405, https://doi.org/10.1111/jfbc.13405 (2020).
65. Akihisa, T. et al. Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects. J. Nat. Prod. 69, 38–42 (2006).
66. Nishimura, R. et al. Isobavachalcone, a chalcone constituent of Angelica keiskei, induces apoptosis in neuroblastoma. Biol. Pharm. Bull. 30, 1878–1883 (2007).
67. Zhao, S. et al. Autophagy inhibition enhances isobavachalcone-induced cell death in multiple myeloma cells. Int. J. Mol. Med. 30, 939–944 (2012).
68. Szliszka, E., Jaworska, D., Ksiek, M., Czuba, Z. P. & Krol, W. Targeting death receptor TRAIL-R2 by chalcones for TRAIL-induced apoptosis in cancer cells. Int. J. Mol. Sci. 13, 15343–15359 (2012).
69. Yang, L. et al. Isobavachalcone reveals novel characteristics of methusisis-like cell death in leukemia cells. Chem. Biol. Interact. 304, 131–138 (2019).
70. Kuete, V. et al. Cytotoxicity of three naturally occurring flavonoid derived compounds (artocarpesin, cycloartocarpesin and isobavachalcone) towards multi-factorial drug-resistant cancer cells. Phytomedicine 22, 1096–1102 (2015).
71. Szliszka, E. et al. Chalcones enhance TRAIL-induced apoptosis in prostate cancer cells. Int. J. Mol. Sci. 11, 1–13 (2009).
72. Ohno, O. et al. Inhibitory effects of bakuchiol, bavachin, and isobavachalcone isolated from Piper longum on melanin production in B16 mouse melanoma cells. Biosci. Biotechnol. Biochem. 74, 1504–1506 (2010).
73. Ma, T. et al. Determination of isobavachalcone in rat plasma by LC-MS/MS and its application to a pharmacokinetic study. J. Pharm. Biomed. Anal. 107, 50–55 (2015).
74. Pietrocola, F. et al. Caloric restriction mimetics enhance anticancer immuno-surveillance. Cancer Cell 30, 147–160 (2016).
75. Ando, S. et al. DNA-binding characteristics of aclorubicin as compared with daunorubicin and doxorubicin. Anticancer Res. 8, 409–415 (1988).
76. Kepp, O. & Kroemer, G. Autophagy induction by thiostrepton for the improvement of anticancer therapy. Autophagy 16, 1166–1167 (2020).
77. Kim, D. H. et al. Modulation of inducible nitric oxide synthase expression in LPS-stimulated BV-2 microglia by prenylated chalcones from Gaulin corylifolium (L.) Medik through inhibition of HapppaBalpha degradation. Molecules 23, https://doi.org/10.3390/molecules23010109 (2018).
78. Innok, P., Rukachaisirikul, T. & Suksamrarn, A. Flavonoids and pterocarpans from the bark of Erythrina fusca. Chem. Pharm. Bull. (Tokyo) 57, 993–996 (2009).
79. Yang, Y., Wang, H. Q. & Chen, R. Y. Flavonoids from the leaves of Morus alba L. Yao Xue Xue Bao 45, 77–81 (2010).
80. Miller, V. et al. Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study. Lancet 390, 2037–2049 (2017).
81. Dalgaard, F. et al. Associations between habitual flavonoid intake and hospital admissions for atherosclerotic cardiovascular disease: a prospective cohort study. Lancet Planet Health 3, e450–e459 (2019).
82. Wang, Y. et al. Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy. J. Immunother. Cancer 8, https://doi.org/10.1136/jitc-2019-000462 (2020).
83. Pietrocola, F. et al. Aspirin recapitulates features of caloric restriction. Cell Rep. 22, 2395–2407 (2018).
84. Enot, D. P., Vacchelli, E., Jacquelot, N., Zitvogel, L. & Kroemer, G. TurnGrowth: an open-access web tool for the statistical analysis of tumor growth curves. Oncoimmunology 7, e1462431 (2018).